Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial

NCT02705638 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02705638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02705638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2016
Completion date
April 30, 2019
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune pancreatitis, igg4-related disease, igg4-related sclerosing cholangitis, immunoglobulin g subclass 4 related disease, retroperitoneal fibrosis